2nd Quarter - Report

TARPLIN STRATEGIES LLC for GENENTECH, INC.

Firm
Client
Income
$75,000
Expenses
—

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

H.R. 3200 and S.----, America's Affordable Health Choices Act of 2009 - government reimbursement for biotherapeutics, comparative effectiveness research, and legislative and regulatory issues involved in FDA approval of follow-on biologics.

LobbyistCovered position, as disclosed
RICHARD JOSEPH TARPLIN and Families

Contacted: Executive Office of the President (EOP); Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 3200 (111th)

Medicare/Medicaid MMM

H.R. 3200 and S. ----, America's Affordable Health Choices Act of 2009 - government reimbursement for biotherapeutics. S. Con. Res. 13, Concurrent Resolution on the Budget, FY 2010 - government reimbursement for biotherapeutics. H. Con. Res. 85, Concurrent Resolution on the Budget, FY 2010 - government reimbursement for biotherapeutics.

LobbyistCovered position, as disclosed
RICHARD JOSEPH TARPLIN and Families

Contacted: SENATE; Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP)

Bills named: H.R. 3200 (111th), S.Con.Res. 13 (111th), H.Con.Res. 85 (111th)

Pharmacy PHA

H.R. 1548, the Pathway for Biosimilars Act, FDA approval of follow-on biologics. H.R. 1427 and S. 726, the Promoting Innovation and Access to Life-Saving Medicine Act, FDA approval of follow-on biologics. H.R. 3200 and S. -----, the Affordable Health Choices Act - FDA approval of follow-on biologics and length of data exclusivity period.

LobbyistCovered position, as disclosed
RICHARD JOSEPH TARPLIN and Families

Contacted: SENATE; Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB)

Bills named: H.R. 1427 (111th), S. 726 (111th), H.R. 1548 (111th), H.R. 3200 (111th)

Medical/Disease Research/Clinical Labs MED

Public Law 111-5, the American Recovery and Reinvestment Act of 2009 - funding for comparative effectiveness research. S. 1213, the Patient-Centered Outcomes Research Act of 2009 - authorization for comparative effectiveness research. S. Con. Res. 13, Concurrent Resolution on the Budget, FY 2010 - government uses of comparative effectiveness research. H. Con. Res. 85, Concurrent Resolution on the Budget, FY 2010 - government uses of comparative effectiveness research.

LobbyistCovered position, as disclosed
RICHARD JOSEPH TARPLIN and Families

Contacted: Executive Office of the President (EOP); SENATE; Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES

Bills named: S.Con.Res. 13 (111th), H.Con.Res. 85 (111th), S. 1213 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.